221 related articles for article (PubMed ID: 25333846)
1. Epigenetic signatures as prognostic tools in acute myeloid leukemia and myelodysplastic syndromes.
Christopeit M; Bartholdy B
Epigenomics; 2014; 6(4):371-4. PubMed ID: 25333846
[No Abstract] [Full Text] [Related]
2. Epigenetics in AML.
Melnick AM
Best Pract Res Clin Haematol; 2010 Dec; 23(4):463-8. PubMed ID: 21130408
[TBL] [Abstract][Full Text] [Related]
3. Genetic Testing in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Nardi V; Hasserjian RP
Surg Pathol Clin; 2016 Mar; 9(1):143-63. PubMed ID: 26940274
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic modifications in AML and MDS.
Mahmud M; Stebbing J
Leuk Res; 2010 Feb; 34(2):139-40. PubMed ID: 19665226
[No Abstract] [Full Text] [Related]
5. Epigenetic modifications of splicing factor genes in myelodysplastic syndromes and acute myeloid leukemia.
Wong JJ; Lau KA; Pinello N; Rasko JE
Cancer Sci; 2014 Nov; 105(11):1457-63. PubMed ID: 25220401
[TBL] [Abstract][Full Text] [Related]
6. [Epigenetic dysregulation in myelodysplastic syndrome].
Sashida G; Iwama A
Rinsho Ketsueki; 2015 Feb; 56(2):111-8. PubMed ID: 25765789
[TBL] [Abstract][Full Text] [Related]
7. CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes.
Benetatos L; Hatzimichael E; Dasoula A; Dranitsaris G; Tsiara S; Syrrou M; Georgiou I; Bourantas KL
Leuk Res; 2010 Feb; 34(2):148-53. PubMed ID: 19595458
[TBL] [Abstract][Full Text] [Related]
8. The role of epigenetics in the regulation of apoptosis in myelodysplastic syndromes and acute myeloid leukemia.
Karlic H; Herrmann H; Varga F; Thaler R; Reitermaier R; Spitzer S; Ghanim V; Blatt K; Sperr WR; Valent P; Pfeilstöcker M
Crit Rev Oncol Hematol; 2014 Apr; 90(1):1-16. PubMed ID: 24183913
[TBL] [Abstract][Full Text] [Related]
9. Clinical applications of epigenetic markers and epigenetic profiling in myeloid malignancies.
McDevitt MA
Semin Oncol; 2012 Feb; 39(1):109-22. PubMed ID: 22289497
[TBL] [Abstract][Full Text] [Related]
10. Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions.
Benetatos L; Dasoula A; Hatzimichael E; Syed N; Voukelatou M; Dranitsaris G; Bourantas KL; Crook T
Ann Hematol; 2011 Sep; 90(9):1037-45. PubMed ID: 21340720
[TBL] [Abstract][Full Text] [Related]
11. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
[TBL] [Abstract][Full Text] [Related]
12. Dynamics of telomere erosion and its association with genome instability in myelodysplastic syndromes (MDS) and acute myelogenous leukemia arising from MDS: a marker of disease prognosis?
Sieglová Z; Zilovcová S; Cermák J; Ríhová H; Brezinová D; Dvoráková R; Marková M; Maaloufová J; Sajdová J; Brezinová J; Zemanová Z; Michalová K
Leuk Res; 2004 Oct; 28(10):1013-21. PubMed ID: 15289012
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia.
McGraw KL; Nguyen J; Komrokji RS; Sallman D; Al Ali NH; Padron E; Lancet JE; Moscinski LC; List AF; Zhang L
Haematologica; 2016 Aug; 101(8):e320-3. PubMed ID: 27081179
[No Abstract] [Full Text] [Related]
14. The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia.
Gonzalez-Lugo JD; Chakraborty S; Verma A; Shastri A
Semin Hematol; 2021 Jan; 58(1):56-65. PubMed ID: 33509444
[TBL] [Abstract][Full Text] [Related]
15. Myelodysplastic syndromes (MDSs) and acute myelogenous leukemia (AML) comprise a closely linked continuum of malignant hematologic diseases. Introduction.
Baylin SB; Mufti GJ
Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S1-3. PubMed ID: 16341235
[No Abstract] [Full Text] [Related]
16. DNMT3A R882 mutations in patients with cytogenetically normal acute myeloid leukemia and myelodysplastic syndrome.
El Ghannam D; Taalab MM; Ghazy HF; Eneen AF
Blood Cells Mol Dis; 2014; 53(1-2):61-6. PubMed ID: 24512939
[TBL] [Abstract][Full Text] [Related]
17. Does therapy-related AML have a poor prognosis, independent of the cytogenetic/molecular determinants?
Feldman EJ
Best Pract Res Clin Haematol; 2011 Dec; 24(4):523-6. PubMed ID: 22127315
[TBL] [Abstract][Full Text] [Related]
18. Myelodysplastic features in a patient with germline CEBPA-mutant acute myeloid leukaemia.
Yan B; Ng C; Moshi G; Ban K; Lee PL; Seah E; Chiu L; Koay ES; Liu TC; Ng CH; Chng WJ; Koh LP
J Clin Pathol; 2016 Jul; 69(7):652-4. PubMed ID: 27010436
[No Abstract] [Full Text] [Related]
19. Familial myelodysplastic syndrome/acute myeloid leukemia.
Churpek JE
Best Pract Res Clin Haematol; 2017 Dec; 30(4):287-289. PubMed ID: 29156196
[TBL] [Abstract][Full Text] [Related]
20. Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes.
Khan H; Vale C; Bhagat T; Verma A
Semin Hematol; 2013 Jan; 50(1):16-37. PubMed ID: 23507481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
